Small Cap Feast
Small Cap Feast – 29 November 2018
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 920
Total number of AIM Companies trading: 850*
* As at 26 November 2018
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 26 November 2018
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at 26 November 2018
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
SEEIT will be the first UK-listed investment fund of its kind to invest exclusively in the energy efficiency sector. Looking to raise £150m. Due 11 Dec
AJ Bell—one of the largest investment platforms in the UK—Expects to publish prospectus end Nov. FYSep18—revenues up 19% to £89.7 million, profit before tax up 31% to £28.4 million. Secondary sell down, Due December.
Sirius Aircraft Leasing Fund targeting a raise of US$250m – objective is to provide investors with an attractive level of regular income and capital returns through investing primarily in used, single-aisle aircraft. Due 5 Dec
MOD Resources—(ASX:MOD) A$78.7m mkt cap. Copper exploration and development company focused on the central and western Kalahari Copper Belt in Botswana. Introduction only. Due c.26 Nov.
Main Market (Specialist Funds)
The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due end Nov.
Kropz, an emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa, a phosphate project in the Republic of Congo and exploration assets in Ghana, is looking to join AIM. Offer TBC, expected late Nov
Titon holdings—international manufacturer and supplier of ventilation systems and window and door hardware. No capital raise. Due 10 Dec. Mkt cap c.£22m.
Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected early December.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer TBA. Due early Dec
Crossword Cybersecurity PLC* (NEX:CCS)—the technology commercialisation company focusing exclusively on the cyber security sector is investigating the possibility of AIM admission. The Company is proposing to raise up to £2.25 million before the end of December, conditional on Admission.
The Panoply parent company of a digitally native technology services group founded in 2016 with the aim of identifying and acquiring best-of-breed specialist information technology and innovation consulting businesses across Europe, is looking to join AIM. Offer £5m new capital, £400k sell-down, market cap of £30m, expected late 4 Dec 2018.
Chi-Med (HCM.L) 5444p £3.6bn
Multiple Collaborations to Evaluate Combinations of
Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
Today, Chi-Med is announcing the first steps to develop its vascular endothelial growth factor receptor inhibitors, surufatinib and fruquintinib, in combination with various programmed cell death protein-1 monoclonal antibodies in several solid tumor settings:
A global collaboration to evaluate the combination of surufatinib with toripalimab (JS001), a PD-1 monoclonal antibody being developed by Shanghai Junshi Biosciences Co. Ltd.; A global collaboration to evaluate the combination of fruquintinib with sintilimab (IBI308), a PD-1 monoclonal antibody being developed by Innovent Biologics (Suzhou) Co. Ltd.; A collaboration in China to evaluate the combination of surufatinib with HX008, a PD-1 monoclonal antibody being developed by Taizhou Hanzhong Pharmaceuticals, Inc.; and a collaboration in China to evaluate the combination of fruquintinib with genolimzumab (GB226), a PD-1 monoclonal antibody being developed by Genor Biopharma Co. Ltd.
Ariana Resources (AAU.L) 1.47p £15.5m
Results of recent exploration at the Salinbas Gold Project in Turkey. Salinbas is located in the Hot Gold Corridor and is 100% owned by Ariana.
Composite channel-sampling at road cuts along the newly built access road to the Ardala Porphyry returned 12m @ 1.08g/t Au + 32.65g/t Ag + 1.39% Pb + 0.31% Zn; including 3m @ 2.65g/t Au + 118g/t Ag + 5.47% Pb + 1.03% Zn.
Conventional soil sampling partly along the target boundary of the Salinbas Exploration Target returned exceptional results including: 5.02g/t Au + 405g/t Ag + 0.48% Cu + 1.45% Pb + 0.26% Zn.
2,000m of Reverse Circulation (RC) drilling is scheduled to commence in Q2 2019 from freehold land and existing forestry permits.
Hostelworld (HSW.L) 180p £174m
Strengthened management team is now in place; – The strategy is to enhance competitiveness and deliver a return to growth by focusing on investment in core customer acquisition and core platform enhancements; and will be supported by investments during 2019, including an expansion of the existing Porto development centre. “EBITDA for the full year to 31 Dec 2018 is expected to be in line with the Board’s expectations. As communicated at the time of the Company’s interim results in Aug 2018, growth in Group like-for-like gross bookings is likely to be flat for the full year, given the expected declines in our supporting brands. Continued effective management of our cost base, combined with strong ABV, is helping to offset the impact of flat bookings. We continue to see strong underlying cash conversion in 2018. The initiatives identified as part of the strategic review will require additional investment during 2019, with growth in bookings expected to be seen in 2020. However, the Board expects the business to return to modest EDITDA growth in 2019.”
Dignity (DTY.L) 849p £424.7m
“The UK’s only listed provider of funeral related services, acknowledges today’s announcement from the Competition and Markets Authority (“CMA”) regarding the provisional findings of its study into the funerals market and notes its proposal to carry out a full market investigation. Dignity is considering the recommendations in detail and notes the key findings. Dignity has engaged constructively with the CMA since the market study was announced in June 2018 and strongly supports the opportunity to improve standards within the sector and meet the expectations of consumers.”
The CMA today proposed a “major funerals probe after identifying serious concerns”.
Shefa Yamin (SEFA.L) 60p £8.54m
The “precious stone exploration company in Northern Israel, announced a significant increase in the estimated tonnages of mineralised placer (basal) gravels for its Kishon Mid-Reach project following the results of the Note For The Record (“NFTR”) report.
Highlights of results from the report:
Zone 1 hosts approximately 1.1 Mt of mineralised placer (basal) gravels, trebling previous estimates of 350,000 t from the Competent Person’s Report (“CPR”)
Total estimated exploration target for Zones 1-3 of almost 5 Mt”.
Bilby (BILB.L) 94.5p £38.1m
The gas heating, electrical and building services provider, has acquired the entire issued share capital of R. Dunham (UK) limited, an electrical services company, for a maximum cash consideration of £1.4m together with the issuance of 250,000 shares that are subject to a twelve month lock up period.
The acquisition is another important step for Bilby enabling it to broaden its customer base and strengthen its presence in its core London and South East markets.
The cash consideration will be funded from the Company’s existing debt facilities. In the year to 31 Dec 2017 R. Dunham generated unaudited revenues of £3.8m, EBITDA of £242,000, PBT of £158,439 and had net assets of £557,581. On completion of the acquisition, Bilby will be repaying Mark Dunham’s director’s loan (being approximately £250,000).
Asiamet Resources (ARS.L) 4.55p £42.7m
$3.3m / £2.6m placing at 4.25p. The net proceeds from the Placing will primarily be used to:
complete the BKM feasibility study with additional infill drilling program to upgrade inferred resources and provide increased data through geotechnical drilling for mine design parameters. This work will ultimately deliver the final feasibility study for the BKM copper project during H1 2019;
drill walk up targets in the BKM project area, extend the BKZ resource and drill the Baroi prospect, subject to permitting; and
commence CSR programmes on the Beutong copper-gold project and continue to plan and evaluate strategic development options for the Beutong copper-gold project.
Genedrive (GDR.L) 23p £4.3m
The near patient molecular diagnostics company, today announces that it will participate in an international multicentre trial (‘REACH’) to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy setting versus conventional treatment pathways. The study, led by Prof. John Dillon, Professor of Hepatology and Gastroenterology at the University of Dundee and funded by AbbVie will cover up to 40 pharmacies across three sites in Scotland, Wales, and Australia.
The REACH study will focus on people undergoing opiate substitute therapy, a patient population traditionally resistant to travel, suggesting a ‘Test and Treat’ outreach-based diagnostic and treatment pathways could provide an effective solution to the HCV epidemic in this population.
Synectics (SNX.L) 190p £33.8m
The specialist “in the design, integration, control and management of advanced surveillance technology and networked security systems provided an update on trading FYNov18.
Underlying profit before tax for the year ending 30 Nov 2018 is anticipated to be broadly in line with market expectations. Trading in the second half of the year has continued the trends in recent prior periods; in particular a weak performance in the UK on-vehicle security sector has been offset by strong results from global Gaming security. The Group’s year end net cash position is expected to have strengthened to approximately £6.5m (2017: £3.8m), its pipeline of expected new business is somewhat stronger than originally expected, and the Board is increasingly confident of solid progress in the Group’s results in the coming year.
As reported in the Company’s interim results announcement, UK new bus registrations in 2018 are down significantly compared to last year, which has adversely affected Synectics’ on-vehicle security activities. In addition, a large bus operator customer chose not to renew its fleet service contract on terms acceptable to Synectics, and a second customer took its service work in-house. As a result, management has restructured this business area, reducing operating costs by approximately £1.2m in the financial year to 30 Nov 2019.”
OptiBiotix (OPTI.L) 97.19p £82.3m
OptiBiotix “has agreed to grant an exclusive license agreement to Nutrilinea S.R.L. for the production, packaging, and supply of SlimBiome Medical in Europe with the aim of maximizing the financial return for both parties. The agreement secures manufacturing for OptiBiotix’s award winning SlimBiome® weight management product recently granted medical device status and CE mark (RNS: Nov 27 2018). Nutrilinea will formulate and package SlimBiome® Medical in boxes of 30 single sachet doses for sale to its own European partners and OptiBiotix’s growing list of existing and potential international partners.
Nutrilinea has over 15 years’ experience in the design and development of customised formulations and presentations (capsules, tablets, sachets) for the supplement and pharmaceutical industry. Nutrilinea has established an international reputation for providing innovative product formulations and presentations and is one of Europe’s fastest growing providers of food supplements with year on year growth of 30% over the last 5 years and revenues of €70m. Nutrilinea has become a valued partner of OptiBiotix and has been instrumental in the development of the Company’s own brand CholBiome® and the rapid sales growth of OptiBitiox’s LP-LDL products.”
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.